H. Lundbeck A/S (HLUN-B) Fair Value & Analysis
Healthcare · DK · Market cap 42.5B DKK
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 2 days ago
Share price +2.5% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 32.64 – kr 45.91 · fair‑value band kr 43.53 – kr 88.47 · the kr 42.56 price screens below the kr 70.78 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
H. Lundbeck A/S (HLUN-B) currently trades at kr 42.56, while our model-based Fair Value estimate is kr 70.78, implying the stock looks roughly 66.3% undervalued today. We read business quality at 69/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, H. Lundbeck A/S generated revenue of 25.5B DKK at a net margin of 14.6%. Revenue grew 14.3% year over year. It earns a return on equity of 14.9%. Net debt stands at 8.6B DKK. Fundamentals as of Jul 19, 2026
Our scenario range runs from kr 43.53 (bear case) to kr 88.47 (bull case); at kr 42.56, the current price sits below that range. The share trades about 8% below its 52-week high and 34% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 66%, HLUN-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
H. Lundbeck A/S reported revenue of kr 24.4B in FY2025 versus kr 16.3B in FY2021, a compound +10.6%/yr. Reported net income was kr 3.2B in FY2025, compounding +24.7%/yr from FY2021.
Is HLUN-B fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹991.46 | -47% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
| Mankind Pharma Limited MANKIND | ₹2,538 | ₹1,161 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is H. Lundbeck A/S (HLUN-B) undervalued?
What is the fair value of HLUN-B?
What is the quality score of HLUN-B?
What is the revenue of H. Lundbeck A/S (HLUN-B)?
What is the net profit margin of HLUN-B?
Does H. Lundbeck A/S pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full H. Lundbeck A/S analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.